64 related articles for article (PubMed ID: 1846979)
21. Ifosfamide-based three-drug combination regimens in non-small cell lung cancer.
Vokes EE; Masters GA; Mauer AM; Hoffman PC; Watson S; Golomb HM
Semin Oncol; 1998 Feb; 25(1 Suppl 2):19-22. PubMed ID: 9535207
[TBL] [Abstract][Full Text] [Related]
22. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
23. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
[TBL] [Abstract][Full Text] [Related]
25. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
26. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
Bonomi PD; Finkelstein DM; Ruckdeschel JC; Blum RH; Green MD; Mason B; Hahn R; Tormey DC; Harris J; Comis R
J Clin Oncol; 1989 Nov; 7(11):1602-13. PubMed ID: 2553879
[TBL] [Abstract][Full Text] [Related]
27. Carboplatin in non-small cell lung cancer: an update on the Cancer and Leukemia Group B experience.
Green MR; Kreisman H; Doll DC; Lyss AP; Clamon GH; Goutsou M; Perry MC; Propert KJ
Semin Oncol; 1992 Feb; 19(1 Suppl 2):44-9. PubMed ID: 1329222
[TBL] [Abstract][Full Text] [Related]
28. Platinum/etoposide therapy in non-small cell lung cancer.
Bonomi P
Oncology; 1992; 49 Suppl 1():43-50. PubMed ID: 1323811
[TBL] [Abstract][Full Text] [Related]
29. Phase II studies with carboplatin in non-small cell lung cancer.
Gatzemeier U; Heckmayr M; Neuhauss R; Hossfeld D; Achterrath W; Lenaz L
Semin Oncol; 1990 Feb; 17(1 Suppl 2):25-31. PubMed ID: 2154856
[TBL] [Abstract][Full Text] [Related]
30. Prolonged administration of oral etoposide alone or with intravenous carboplatin in stage IV non-small cell lung cancer: a randomized trial.
Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N
Lung Cancer; 1997 Oct; 18(2):179-88. PubMed ID: 9316009
[TBL] [Abstract][Full Text] [Related]
31. Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer.
Hotta K; Matsuo K
J Thorac Oncol; 2007 Jan; 2(1):96. PubMed ID: 17410021
[No Abstract] [Full Text] [Related]
32. Review of therapeutic trials of carboplatin in lung cancer.
Bunn PA
Semin Oncol; 1989 Apr; 16(2 Suppl 5):27-33. PubMed ID: 2541506
[TBL] [Abstract][Full Text] [Related]
33. Carboplatin in the treatment of non-small cell lung cancer: a review.
Comis RL
Oncology; 1993 Nov; 50 Suppl 2():37-41. PubMed ID: 8233300
[TBL] [Abstract][Full Text] [Related]
34. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
Ann Oncol; 1999 May; 10(5):605-7. PubMed ID: 10416014
[TBL] [Abstract][Full Text] [Related]
35. Clinical experiences with carboplatin (paraplatin) in lung cancer.
Bunn PA
Semin Oncol; 1992 Feb; 19(1 Suppl 2):1-11. PubMed ID: 1329216
[TBL] [Abstract][Full Text] [Related]
36. Review of methodological problems in the interpretation of phase II trials in nonsmall-cell lung cancer.
Sørensen JB; Hansen HH
Antibiot Chemother (1971); 1988; 41():57-64. PubMed ID: 2854446
[No Abstract] [Full Text] [Related]
37. Statistical and empirical evaluation of histopathologic reviews for quality assurance in the Eastern Cooperative Oncology Group.
Gilchrist KW; Harrington DP; Wolf BC; Neiman RS
Cancer; 1988 Sep; 62(5):861-8. PubMed ID: 3409167
[TBL] [Abstract][Full Text] [Related]
38. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer.
Hardy D; Liu CC; Cormier JN; Xia R; Du XL
Ann Oncol; 2010 Sep; 21(9):1825-1833. PubMed ID: 20211871
[TBL] [Abstract][Full Text] [Related]
39. Carboplatin in non-small cell lung cancer: review of the Eastern Cooperative Oncology Group trial and comparison with other carboplatin trials.
Bonomi P
Semin Oncol; 1991 Feb; 18(1 Suppl 2):2-7. PubMed ID: 1846979
[TBL] [Abstract][Full Text] [Related]
40. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
